Bowman Bagley - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)

Reporting relationship: VP Commercial North America
Issuer ticker: CLGN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 10:18:28 UTC
Source filing: View source filing
Reporting owner signature: /s/ Bowman Bagley

Key filing fact

Bowman Bagley filed Form 3 for CollPlant Biotechnologies Ltd (CLGN) on 18 Mar 2026.

Key facts

This page summarizes Bowman Bagley's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 10:18.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002117210 Primary reporting owner

Bagley Bowman

Relationship: VP Commercial North America
Address: C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
Signature: /s/ Bowman Bagley
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLGN holding

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,000
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The restricted share units shall vest over a period of 4 years as follows: 25% shall vest on January 1, 2027, and the remaining 75% shall vest in twelve equal quarterly installments thereafter.